Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis.

Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis. Am J Pathol. 2006 Sep; 169(3):1012-25.

View in: PubMed

subject areas

Aminoimidazole Carboxamide
AMP-Activated Protein Kinases
Animals
Dose-Response Relationship, Drug
Drug Evaluation, Preclinical
Drug Therapy, Combination
Encephalomyelitis, Autoimmune, Experimental
Enzyme Activation
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypoglycemic Agents
Immunoglobulin G
Immunologic Factors
Lovastatin
Multienzyme Complexes
Multiple Sclerosis
Myelin Basic Protein
Rats
Rats, Inbred Lew
Ribonucleotides
Th1 Cells
Th2 Cells

authors with profiles

Avtar K. Singh
Inderjit Singh
Manjeet Kaur Paintlia